TS03 Inc Trust Units TSTIF

RE:TSO3 Takeover.

[echo2]

This news is piling up with Olympus starting to settle confidentially and without prejudice of accepting liability with plaintiffs for all the wrongful deaths beginning one by one with these 2 in Seattle (out of a total of 18? there!) and dozens elsewhere, with additional hundreds and hundred patients injured and infected from contaminated scopes... And, there continues to be injury and possibly deaths: "A recent analysis of medical device reports indicates that the number of reports associated with patient infections peaked in 2015 at 250 reports and has declined 62% to fewer than 100 reports a year in 2017 and 2018," the FDA's Shuren said. 

In addition to the $85 M to DoJ, and the Olympus executive's guilty plea… US lawyers are all over this… https://lawsuits.lawinfo.com/OlympusScopes/index.html 

And, note that in Canada and elsewhere that reporting of incidents of patient injury or contamination are voluntary by OEM's with NO established guidelines for ongoing surveillance by end users or OEM's. The big news for Olympus is that they were caught not reporting the existence of the scope contamination problem. And, while the FDA has not yet reported the main factors in their post-market surveillance contamination remains unacceptable despite company IFU’s and best cleaning practices….TSO3 provides the only FDA recognized solution for this problem!

Olympus appears to be finally getting their ducks in a row to try to move on and leave this contamination problem in the past, but their present protocols and published IFU's are not solving their, and patients', problems… What can they do now to mitigate? 

Fortive overpaid for ASP (their supposedly new technology that will restore them to being leaders in the field is rumoured to be only another ‘just-in-time’ competitor to Steris’s 1e and Cantel's new similar liquid HLD unit) which, while good, are not terminal sterilization products (scopes thus processed must be used immediately and can't be stored sterile for future use). (I can't believe they haven't started bidding for TSO3.)

TSO3's new terminal sterilization technology that solves Olympus's problem is the biggest duck in their gallery…

Once TSO3 reports more early traction (?25-?30) positive sales for their first full quarter since taking charge of marketing, sales, installs, and service and once they meet their target of 200+ more units sold and installed through 2019, this will show TSO3 has made it in this market, but the share price won't still be in the .50 range at that time. I realize most acquirers want buy a company that is de-risked and immediately accretive to cash flow and profit, but once TSO3 is de-risked, they will have to pay many many mulitples of the present share price for it.

TSO3 has an enthousiastic new sales force in place. They are beginning to execute. They need to show us that they can make this story a screaming success!

Don’t sell under $2.00 US in the near term!!! This company is extremely undervalued following recent market sales by a couple of funds and others taking losses for tax purposes before the year end and TOS is worth far more than $2.00!!!